FDA studying if gel for diabetic ulcers causes cancer

Article

Regranex is being studied by the FDA on whether it is linked to higher rates of cancer.

Is Regranex (becaplermin, Johnson & Johnson) Gel, which helps heal foot and leg diabetic ulcers, associated with higher rates of cancer death? That?s what the Food & Drug Administration is now studying. In an early company.

To see more Daily News articles, click here.

To go to the Drug Topics homepage, clickhere.

Recent Videos
Related Content
Q&A: How Pharmacists Can Help Patients with COPD, Inhaler Misuse | ASHP Midyear

Q&A: How Pharmacists Can Help Patients with COPD, Inhaler Misuse | ASHP Midyear

Brian Nowosielski;Lourdes Cross, PharmD, BCACP, CDCES;Ashley Gallagher
December 17th 2024
Article

Drug Topics met with Lourdes Cross, PharmD, BCACP, CDCES, to discuss pharmacists’ role in managing patients’ chronic obstructive pulmonary disease.

Looking to the Future of Independent Pharmacy

Looking to the Future of Independent Pharmacy

Miranda Hester
July 13th 2022
Podcast

Don Arthur, RPh, discusses what lays ahead in independent pharmacy, from clinical care to success stories.

Ambulatory Care Pharmacists to Decrease PCP Workload, Increase Patient Access | ASHP Midyear

Ambulatory Care Pharmacists to Decrease PCP Workload, Increase Patient Access | ASHP Midyear

Brian Nowosielski
December 16th 2024
Article

Experts conducted a study to better understand how ambulatory care pharmacist services impacted patient outcomes, provider workload, and access to care.

Podcast: Pharmacy Financing With First Financial Bank

Podcast: Pharmacy Financing With First Financial Bank

January 28th 2022
Podcast

Learn more about the ins and outs of pharmacy ownership from the experts at First Financial Bank.

Tapinarof Cream 1% Approved by FDA to Treat Atopic Dermatitis in Adults, Children 2 Years and Older

Tapinarof Cream 1% Approved by FDA to Treat Atopic Dermatitis in Adults, Children 2 Years and Older

Killian Meara
December 16th 2024
Article

Vtama from Organon was previously approved in May 2022 to treat plaque psoriasis in adults.

Q&A: Pharmacists’ Understanding of CKD Therapies, Adverse Effects | ASHP Midyear

Q&A: Pharmacists’ Understanding of CKD Therapies, Adverse Effects | ASHP Midyear

Brian Nowosielski;Denise Kelley, PharmD, BCPS, FASHP ;Ashley Gallagher
December 13th 2024
Article

Denise Kelley, PharmD, BCPS, FASHP, joined Drug Topics to discuss various medications for chronic kidney disease and their common adverse reactions.

© 2024 MJH Life Sciences

All rights reserved.